Article by High! Canada
Founded in Toronto in 2016,Strainprint Technologies Ltd. is the leading demand-side cannabis data and analytics company, gathering real-time cannabis consumption and efficacy data on lab-verified strains.
Strainprint data supports global cannabis research and provides advanced business intelligence and treatment guidance to producers, retailers, medical practitioners, pharma, government and industry. Strainprint is HIPAA, PIPEDA and PHIPA privacy compliant, military-grade encrypted and all patient data is completely anonymized and at rest in Canada. Strainprint can be seamlessly embedded or integrated with most electronic medical records (EMR) and seed2sale software systems.
Strainprint Analytics is accessed by customer subscription. The Strainprint App is free to patients and can be downloaded from both the iOS App Store and GooglePlay Store. www.strainprintanalytics.com
Who is Strainprint?
Our mission is to help people use cannabis in the most effective way possible. By guiding patients to track their own cannabis intake, we will help to refine and improve treatment. It is our aim to advance the scientific understanding of cannabis and its legitimization as a therapy.
Andrew Muroff is our Chief Executive Officer. Andrew is a hands-on entrepreneur that has led public and private technology companies since 1995. To Strainprint, he brings deep corporate and financial experience, broad expertise across regulated cannabis markets in Canada and the U.S., and a passion to help people. He is a published legal author with graduate degrees in Business and Law and is a member of the State Bar of Michigan. Hailing from “South Detroit” – a.k.a. Windsor, Ontario – Andrew and his wife of 20 years have 2 amazing kids with whom they explore the world. In his spare time, he builds custom electric guitars and regularly performs in a number of rock and roll outfits.
David Berg is our President & Chief Technology Officer. David is responsible for the on-going development of the Strainprint application and emerging analytic products. David works directly with the company’s developers, customers, partners, physicians and clinicians to deliver on the vision of a crowdsourced medical cannabis tracking ecosystem. David has a broad technical and business background with over 20 years of experience managing product and engineering teams for major multi-national technology companies. David has spent the last 3 years working in the medical cannabis industry and has experience working in commercial cultivation and distribution in Holland, Jamaica and Canada. David has a degree in finance and marketing from York University and a Masters in Business Administration from the University of Windsor.
Stephanie Karasick is our Chief Creative Officer. Stephanie was born and raised in the suburbs of Montreal and left shortly after getting her degree in Graphic Design. She moved to Toronto, working as a copywriter at Leo Burnett, Saatchi & Saatchi, JWT, Taxi, and MacLaren McCann over a span of 15 years. Somewhere in that time, she began studying photography, left the corporate world to work as an editorial and family photographer, and a mom. The idea for Strainprint came to her after her first few months of using medical cannabis, when she was noticing how little information and scientific validation there was on various treatments.
Evan Karasick is our Chief of Customer Care. Evan has been an innovator in the digital space for more than 20 years. Along with his expertise and passion for Strainprint, Evan is the principal and founder of Channel 1 Media, a digital marketing agency that specializes in the creation of customized sales tools for over 180 sports franchises and venues in North America and Europe. Born and raised in Vancouver, BC, Evan holds a B. Comm in Urban Land Economics from the University of British Columbia, and a Piano Performance Degree from The Royal Conservatory of Music. He currently makes his home in Toronto, with his wife and two daughters.
What is Strainprint Analytics?
Strainprint Analytics business intelligence platform is built on top of North America’s largest longitudinal medical cannabis study, Strainprint Analytics has over 400,000 tracked medical outcomes and over 6 million data points on strain efficacy and actual ACMPR patient use. The Strainprint Analytics platform is shaping the global cannabis industry by empowering clinics, LP’s, retailers, Pharma and government with real-time decision support tools, while helping thousands of ACMPR patients to successfully treat a variety of symptoms and live healthier lives.
•The Strainprint journaling app guides patients on what works best for them and at the same time drives a massive global data set.
•Strainprint’s industry-leading cannabis journal & outcomes tracking app is available to patients and doctors for FREE on both iOS and Android.
•Data collected from the mobile app is analyzed to provide patients with a personalized strain efficacy scoring, based on real-world treatment experience.
•Data from the global user base is cleansed, anonymized and amalgamated in an enterprise-class, secure cloud-based platform.
•Producers, retailers, clinicians, researchers etc. subscribe to access Strainprint data through the Strainprint Analytics web-portal.
Where can people find Strainprint? The Strainprint App is free to patients and can be downloaded from both the iOS App Store and GooglePlay Store. We can be found at strainprint.ca
For an industry that is interested in our data and analytics, they can reach out to us directly. We anticipate our companion app strainprint analytics edition to be available as of summer, 2018. We look forward to that launch! Currently, we work with many industry leaders including, but not limited to 48 North, Emblem, Canna Farms, Peace Naturals, Grow Wise Health, Flowr and SheCann. The only way we can craft public policy on Cannabis is to know the facts on strain efficacy and patient use.
This is why we are so pleased to Introduce Strainprint TM Analytics. The most comprehensive data platform built on the most comprehensive patient data available today.
Can you tell us more about why you launched Strainprint’s Business Intelligence Platform – Strainprint Analytics?
Strainprint is a company that is made up of medical cannabis patients, developing solutions for medical cannabis patients. The company really came about out of necessity and serendipity. At the time that we were introduced, we were all working on a number of different Cannabis cultivation and infrastructure projects at the same time and we were all dealing with family members that were using Cannabis to treat a number of complex medical conditions.
We all share the vision that Cannabis can provide a great deal of value to patients around the world but that it was lacking legitimacy due to a lack of controlled study.
At the time, we were doing a great deal of research regarding cannabis and its use for autoimmune and inflammatory diseases and was surprised that there were no good sources of published information. We took the time to talk to numerous physicians and clinical researchers but realized that there was very little knowledge. This caused us to dig deeper and we were appalled to find out that there were no studies of material substance – globally.
It was at this point we realized that this prototype application, which at the time was called WeeDR became very interesting to us. It was even more obvious to us the power that a crowdsourced application could provide for the widespread study of Cannabis as a medical tool. This is when we all decided to get together to really develop Strainprint into a tool that could really help people and build a base of research that could help patients, physicians, researchers, therapeutics companies and others, to usher in a wave of next-generation therapies. The interesting exercise was to build a tool that was easy for patients with a broad range of medical conditions and symptoms to use. It’s not an easy thing to build a tool that can track over 350 medical conditions, over 3500 lab verified strains and 12 ingestion methods – but it has been a learning experience and fun. Then we had to find a way to make it secure and private for both Canadian and American patients – to that end we made sure that the solution was HIPAA, PIPEDA and PHIPA compliant.
The amazing thing about working on this project is the level of passion and engagement seen in everyone we work with – patients, doctors, researchers, licensed producers, pharmacists and other software companies – it is incredibly rewarding!
We spent the better part of two years developing the solution. Last year we launched the Strainprint mobile App for patients on the Google Play and Apple AppStore. In a little over a year, we have collected well over 6 million data points and 400,000 lab verified medication sessions. It is exciting to see that every month we see thousands of new patients join the platform – it has really taken on a life of its own.
Two weeks ago we launched Strainprint Analytics our business intelligence and decision support solution for the medical cannabis industry. This web-based analytics tool enables doctors, researchers, clinics and producers to analyze the anonymous Strainprint data to better understand the way patients are using cannabis to treat a wide array of conditions and symptoms. Perhaps as is important is mapping the patient-rated outcomes against the chemical composition data that we collect from ACMPR lab verified sources.
Analyzing patient response patterns against the chemical composition (cannabinoid, terpene and flavonoid) combined with dosing and ingestion method information is helping us to uncover the true medicinal properties of this amazing plant. Strainprint is here to provide the community with the data that is needed to advance research and product development to meet the growing needs of our patient base.
At the end of the day, it is all about helping people. This is who we are at Strainprint and this is what we do.
Tell us about where Strainprint is right now?
After 6 months of development and a month of quality assurance testing, we introduced Strainprint Analytics last month in Ottawa to provide first-hand evidence to our government that Strainprint has a mountain of scientific data on ACMPR medical cannabis strains and patient use. Specifically, that’s almost 400,000 medical records from tens of thousands of ACMPR patients who have tracked their medical outcomes using our mobile app. We’re not talking about qualitative “reviews” like you find on Leafly or Lift, but rather research-focused (doctor-designed) medical outcomes of strain efficacy and real-world use. It is by far the largest and most granular data set of its kind in the world with over 6 million data points…and it’s growing by ~30% per month.
We specifically launched in Ottawa, because our federal and provincial governments are scrambling right now to define public policy for the future of recreational cannabis use in Canada. We have heard over and over again that they need to collect more data and need more time to consider it. We wanted to prove that the data is ready for them to consider right now in real-time on Strainprint Analytics. It’s not only incredibly valuable for producers and clinics that serve medical patients, but also for serving recreational customers and for driving public policy decisions around things like, employee education, workplace cannabis use, packaging and labeling and better understanding impairment. There are also a ton of research applications that caught the government’s attention, including eldercare and palliative care studies that can potentially reduce the financial impact on the various levels of government.
We have now begun rolling out Strainprint Analytics access to all of our LP, clinic and biotech customers, who have been patiently waiting for us it to be able to visualize the industry and patient data. On top of that, we recently attended the Canadian Consortium for the Investigation of Cannabinoids (CCIC) conference in Toronto and had the opportunity to demo Strainprint Analytics to about a dozen new LPs and clinics and variety of physicians. The reaction was unanimous excitement and the feedback is that there’s nothing like it anywhere in the world, let alone Canada.
In the coming months, you can expect to see more and more LP’s and clinics rolling out mobile app activation codes to their patients and using Strainprint Analytics for business intelligence and making better treatment recommendations, based on real data. We’re also beginning to expand our sales efforts into Europe, Australia, Latin America, and key, legal markets in the U.S. On the technology front, we’re deep into integrations with various Seed-2-sale, EMR and EComm platforms. In 2018, we’re also going to be releasing dedicated versions of Strainprint Analytics for clinics, pharmacies, patients and later this year a version for recreational (adult-use) stakeholders. Lots of work to do!